|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0012863,
umls-concept:C0013162,
umls-concept:C0040715,
umls-concept:C0243077,
umls-concept:C0332257,
umls-concept:C0598894,
umls-concept:C0599718,
umls-concept:C0599813,
umls-concept:C0599893,
umls-concept:C1514463,
umls-concept:C1522702
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1991-3-8
|
|
pubmed:abstractText |
The present case, together with other reports reviewed herein, defines a new subtype of therapy-related acute myeloid leukemia (t-AML). This variant of t-AML is characterized by a short interval from initial drug therapy to bone marrow dysfunction and monocytic morphology without trilineage dysplasia. Unlike classic t-AML, which frequently has abnormalities of chromosomes 5 and/or 7, this new subtype is characterized by rearrangements involving band q23 of chromosome 11, most commonly a 9;11 translocation. The majority of patients with this subtype t-AML had prior cytotoxic therapy with topoisomerase II-reactive drugs including anthracyclines, epipodophyllotoxins, or actinomycin D, combined with either an alkylating agent or cisplatin. This association of prior therapy which includes topoisomerase II-reactive agents and a rapidly appearing t-AML involving the monocytic line and chromosome 11 requires additional study.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1045-2257
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
53-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:2177642-Alkylating Agents,
pubmed-meshheading:2177642-Antibiotics, Antineoplastic,
pubmed-meshheading:2177642-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2177642-Breast Neoplasms,
pubmed-meshheading:2177642-Chromosomes, Human, Pair 11,
pubmed-meshheading:2177642-Chromosomes, Human, Pair 9,
pubmed-meshheading:2177642-Cisplatin,
pubmed-meshheading:2177642-Combined Modality Therapy,
pubmed-meshheading:2177642-Cyclophosphamide,
pubmed-meshheading:2177642-Dactinomycin,
pubmed-meshheading:2177642-Doxorubicin,
pubmed-meshheading:2177642-Humans,
pubmed-meshheading:2177642-Iatrogenic Disease,
pubmed-meshheading:2177642-Leukemia, Monocytic, Acute,
pubmed-meshheading:2177642-Mastectomy, Radical,
pubmed-meshheading:2177642-Middle Aged,
pubmed-meshheading:2177642-Podophyllotoxin,
pubmed-meshheading:2177642-Radiotherapy,
pubmed-meshheading:2177642-Tamoxifen,
pubmed-meshheading:2177642-Topoisomerase II Inhibitors,
pubmed-meshheading:2177642-Translocation, Genetic
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation.
|
|
pubmed:affiliation |
Department of Medicine, Loyola University Stritch School of Medicine, Maywood, IL 60153.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Review,
Case Reports,
Research Support, Non-U.S. Gov't
|
